JCL roundtable: HDL in the primary care setting

Journal of Clinical Lipidology

Volumn 8, Issue 4, 2014, Pages 364-372

  Brown, W Virgil ^a   Ansell, Benjamin J ^b   Mackey, Rachel H ^c   Toth, Peter P ^d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d CGH MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; HDL cholesterol; Hdl C; Metabolism; Primary care

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER;

CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL RESEARCH; GENERAL PRACTITIONER; HUMAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); EXPERT WITNESS; METABOLISM; MOLECULARLY TARGETED THERAPY; TRANSLATIONAL RESEARCH; TRENDS;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CLINICAL TRIALS AS TOPIC; EXPERT TESTIMONY; HUMANS; MOLECULAR TARGETED THERAPY; PHYSICIANS, PRIMARY CARE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84905923064     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2014.05.009     Document Type: Review

References (9)

1. Mackey RH, Greenland P, Goff DC Jr., Lloyd-Jones D, Sibley CT, Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2012;60(6): 508-516.
2. Mora S, Glynn RJ, Ridker PM. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation. 2013;128:1189-1197.
3. El Harchaoui K, Arsenault BJ, Franssen R, et al. High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med. 2009;150(2):84-93.
4. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006.
5. Airan-Javia SL, Wolf RL, Wolfe ML, Tadesse M, Mohler E, Reilly MP. Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low-and high-dose simvastatin monotherapy. Am Heart J. 2009;157:687-688.
6. Ballantyne CM, Miller M, Niesor EJ, Burgess T, Kallend D, Stein EA. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. Am Heart J. 2012; 163(3):515-521, 521.e1-3. http://dx.doi.org/10.1016/j.ahj.2011.11.017.
7. Toth PP, Barter PJ, Rosenson R, et al. National Lipid Association Consensus on the Clinical Significance and Management of Low Serum levels of HDL-C. J Clin Lipidol. 2013;7(5):484-525.
8. Toth PP, Barylski M, Nikolic D, Rizzo M, Montalto G, Banach M. Should low high-density lipoprotein cholesterol (HDL-C) be treated? Best Pract Res Clin Endocrinol Metab. 2014;28:353-368.
9. Barylski M, Toth PP, Nikolic D, Banach M, Rizzo M, Montalto G. Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Pract Res Clin Endocrinol Metab. 2014;28:453-461.